Hypotheses [Outliers]

posted by Loky do – Egypt, 2021-07-06 13:51 (876 d 07:29 ago) – Posting: # 22458
Views: 2,682

Thanks, Helmut for your reply

but I am quite confused, some products show high intrasubject variability more than anticipated or published in the literature and I think this variability affect the reliability of results, for example, I have a BE study for (lansoprazole), partially replicate design, the published intrasubject variability ~ 40% but the practical intrasubject variability we had was near 85% :confused: study protocol also stated using ema guidelines for scaling but the study failed, when I used FDA method it passes :confused: does this high variability have a role in this confusing results? also in the future protocol can I specify that if the intrasubject variability is more than 50% can I switch to the FDA method for calculation, as many authorities we submit our studies to follow ema guidelines?

Thanks in advance

Complete thread:

UA Flag
 Admin contact
22,811 posts in 4,783 threads, 1,639 registered users;
15 visitors (0 registered, 15 guests [including 8 identified bots]).
Forum time: 20:20 CET (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz